3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Lymphoma, Follicular
5
Breast Neoplasms
5
Neoplasm Metastasis
4
Lymphoma, Non-Hodgkin
4
Lymphoma
4
Waldenstrom Macroglobulinemia
3
Pancreatic Neoplasms
3
Neoplasms
3
Melanoma
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, B-Cell, Marginal Zone
3
Lymphoma, Mantle-Cell
2
Leukemia
2
Glioma
2
Glioblastoma
2
Colorectal Neoplasms
2
Burkitt Lymphoma
2
Brain Neoplasms
2
Virus Diseases
1
Uterine Cervical Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Select Advanced Solid Tumors
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pain
1
Neuroectodermal Tumors
1
Neuroblastoma
1
Nervous System Diseases
1
Interventions
Vincristine
2
Temozolomide
2
Oncolytic Virotherapy
2
repotrectinib
1
pralsetinib
1
pembrolizumab
1
pamiparib
1
interferon gamma-1b
1
cixutumumab
1
Vorinostat
1
Valproic Acid
1
Thiotepa
1
Sunitinib
1
Radiotherapy
1
Radiation
1
Peripheral Blood Stem Cell Transplantation
1
ONC206
1
Melphalan
1
Maintenance Chemotherapy
1
Lomustine
1
Interleukin-12
1
Interferon-gamma
1
Immunotherapy
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Etoposide
1
Erlotinib Hydrochloride
1
Doxorubicin
1
Cyclophosphamide
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neuroectodermal Tumors
×
Antibodies, Monoclonal
×
Clear all
NCT02798406
2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2
Completed
49 enrolled